New Face For Dr Reddy’s Dermatology Business
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In what could be a significant push to its dermatology business in the U.S., Dr Reddy's Labs has carved out a new company - Promius Pharma to establish a distinct identity for its branded specialty products
You may also be interested in...
Dr. Reddy’s dermatologicals
The Indian drugmaker plans to launch three branded dermatological products in the U.S. by the end of 2009 through its newly-established Bridgewater, N.J.-based Promius Pharma subsidiary. The products, which were in-licensed and co-developed, include: EpiCeram skin barrier emulsion for atopic dermatitis, Scytera foam for psoriasis and Promiseb cream for seborrheic dermatitis. Other topical products are in development. Dr. Reddy's established Promius as a platform for its U.S. branded specialty drug business (1PharmAsia News, Aug. 19, 2008)
Dr. Reddy’s dermatologicals
The Indian drugmaker plans to launch three branded dermatological products in the U.S. by the end of 2009 through its newly-established Bridgewater, N.J.-based Promius Pharma subsidiary. The products, which were in-licensed and co-developed, include: EpiCeram skin barrier emulsion for atopic dermatitis, Scytera foam for psoriasis and Promiseb cream for seborrheic dermatitis. Other topical products are in development. Dr. Reddy's established Promius as a platform for its U.S. branded specialty drug business (1PharmAsia News, Aug. 19, 2008)
Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry
MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business